Report error Found 42 Enz. Inhib. hit(s) with all data for entry = 1581
Affinity DataIC50: 1.20nMAssay Description:RTK inhibitory activity of the compounds 2-12 were evaluated using human tumor cells known to express high levels of EGFR, VEGFR-2 or PDFGR-β us...More data for this Ligand-Target Pair
3D Structure (crystal)
Affinity DataIC50: 3.40nMAssay Description:RTK inhibitory activity of the compounds 2-12 were evaluated using human tumor cells known to express high levels of EGFR, VEGFR-2 or PDFGR-β us...More data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 2(Human)
Duquesne University of The Holy Spirit
US Patent
Duquesne University of The Holy Spirit
US Patent
Affinity DataIC50: 5.80nMAssay Description:RTK inhibitory activity of the compounds 2-12 were evaluated using human tumor cells known to express high levels of EGFR, VEGFR-2 or PDFGR-β us...More data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 2(Human)
Duquesne University of The Holy Spirit
US Patent
Duquesne University of The Holy Spirit
US Patent
Affinity DataIC50: 6.70nMAssay Description:RTK inhibitory activity of the compounds 2-12 were evaluated using human tumor cells known to express high levels of EGFR, VEGFR-2 or PDFGR-β us...More data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 2(Human)
Duquesne University of The Holy Spirit
US Patent
Duquesne University of The Holy Spirit
US Patent
Affinity DataIC50: 12.9nMAssay Description:RTK inhibitory activity of the compounds 2-12 were evaluated using human tumor cells known to express high levels of EGFR, VEGFR-2 or PDFGR-β us...More data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 2(Human)
Duquesne University of The Holy Spirit
US Patent
Duquesne University of The Holy Spirit
US Patent
Affinity DataIC50: 18.6nMAssay Description:RTK inhibitory activity of the compounds 2-12 were evaluated using human tumor cells known to express high levels of EGFR, VEGFR-2 or PDFGR-β us...More data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 2(Human)
Duquesne University of The Holy Spirit
US Patent
Duquesne University of The Holy Spirit
US Patent
Affinity DataIC50: 18.9nMAssay Description:RTK inhibitory activity of the compounds 2-12 were evaluated using human tumor cells known to express high levels of EGFR, VEGFR-2 or PDFGR-β us...More data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 2(Human)
Duquesne University of The Holy Spirit
US Patent
Duquesne University of The Holy Spirit
US Patent
Affinity DataIC50: 19.1nMAssay Description:RTK inhibitory activity of the compounds 2-12 were evaluated using human tumor cells known to express high levels of EGFR, VEGFR-2 or PDFGR-β us...More data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 2(Human)
Duquesne University of The Holy Spirit
US Patent
Duquesne University of The Holy Spirit
US Patent
Affinity DataIC50: 19.9nMAssay Description:RTK inhibitory activity of the compounds 2-12 were evaluated using human tumor cells known to express high levels of EGFR, VEGFR-2 or PDFGR-β us...More data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 2(Human)
Duquesne University of The Holy Spirit
US Patent
Duquesne University of The Holy Spirit
US Patent
Affinity DataIC50: 20.9nMAssay Description:RTK inhibitory activity of the compounds 2-12 were evaluated using human tumor cells known to express high levels of EGFR, VEGFR-2 or PDFGR-β us...More data for this Ligand-Target Pair
TargetPlatelet-derived growth factor receptor alpha(Human)
Duquesne University of The Holy Spirit
US Patent
Duquesne University of The Holy Spirit
US Patent
Affinity DataIC50: 22.8nMAssay Description:RTK inhibitory activity of the compounds 2-12 were evaluated using human tumor cells known to express high levels of EGFR, VEGFR-2 or PDFGR-β us...More data for this Ligand-Target Pair
TargetPlatelet-derived growth factor receptor alpha(Human)
Duquesne University of The Holy Spirit
US Patent
Duquesne University of The Holy Spirit
US Patent
Affinity DataIC50: 24.6nMAssay Description:RTK inhibitory activity of the compounds 2-12 were evaluated using human tumor cells known to express high levels of EGFR, VEGFR-2 or PDFGR-β us...More data for this Ligand-Target Pair
TargetPlatelet-derived growth factor receptor alpha(Human)
Duquesne University of The Holy Spirit
US Patent
Duquesne University of The Holy Spirit
US Patent
Affinity DataIC50: 25nMAssay Description:RTK inhibitory activity of the compounds 2-12 were evaluated using human tumor cells known to express high levels of EGFR, VEGFR-2 or PDFGR-β us...More data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 2(Human)
Duquesne University of The Holy Spirit
US Patent
Duquesne University of The Holy Spirit
US Patent
Affinity DataIC50: 32.3nMAssay Description:RTK inhibitory activity of the compounds 2-12 were evaluated using human tumor cells known to express high levels of EGFR, VEGFR-2 or PDFGR-β us...More data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 2(Human)
Duquesne University of The Holy Spirit
US Patent
Duquesne University of The Holy Spirit
US Patent
Affinity DataIC50: 33.2nMAssay Description:RTK inhibitory activity of the compounds 2-12 were evaluated using human tumor cells known to express high levels of EGFR, VEGFR-2 or PDFGR-β us...More data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 2(Human)
Duquesne University of The Holy Spirit
US Patent
Duquesne University of The Holy Spirit
US Patent
Affinity DataIC50: 38.5nMAssay Description:RTK inhibitory activity of the compounds 2-12 were evaluated using human tumor cells known to express high levels of EGFR, VEGFR-2 or PDFGR-β us...More data for this Ligand-Target Pair
TargetPlatelet-derived growth factor receptor alpha(Human)
Duquesne University of The Holy Spirit
US Patent
Duquesne University of The Holy Spirit
US Patent
Affinity DataIC50: 40.4nMAssay Description:RTK inhibitory activity of the compounds 2-12 were evaluated using human tumor cells known to express high levels of EGFR, VEGFR-2 or PDFGR-β us...More data for this Ligand-Target Pair
TargetPlatelet-derived growth factor receptor alpha(Human)
Duquesne University of The Holy Spirit
US Patent
Duquesne University of The Holy Spirit
US Patent
Affinity DataIC50: 50.1nMAssay Description:RTK inhibitory activity of the compounds 2-12 were evaluated using human tumor cells known to express high levels of EGFR, VEGFR-2 or PDFGR-β us...More data for this Ligand-Target Pair
TargetPlatelet-derived growth factor receptor alpha(Human)
Duquesne University of The Holy Spirit
US Patent
Duquesne University of The Holy Spirit
US Patent
Affinity DataIC50: 58.2nMAssay Description:RTK inhibitory activity of the compounds 2-12 were evaluated using human tumor cells known to express high levels of EGFR, VEGFR-2 or PDFGR-β us...More data for this Ligand-Target Pair
TargetPlatelet-derived growth factor receptor alpha(Human)
Duquesne University of The Holy Spirit
US Patent
Duquesne University of The Holy Spirit
US Patent
Affinity DataIC50: 66.1nMAssay Description:RTK inhibitory activity of the compounds 2-12 were evaluated using human tumor cells known to express high levels of EGFR, VEGFR-2 or PDFGR-β us...More data for this Ligand-Target Pair
Affinity DataIC50: 68.2nMAssay Description:RTK inhibitory activity of the compounds 2-12 were evaluated using human tumor cells known to express high levels of EGFR, VEGFR-2 or PDFGR-β us...More data for this Ligand-Target Pair
TargetPlatelet-derived growth factor receptor alpha(Human)
Duquesne University of The Holy Spirit
US Patent
Duquesne University of The Holy Spirit
US Patent
Affinity DataIC50: 73.2nMAssay Description:RTK inhibitory activity of the compounds 2-12 were evaluated using human tumor cells known to express high levels of EGFR, VEGFR-2 or PDFGR-β us...More data for this Ligand-Target Pair
TargetPlatelet-derived growth factor receptor alpha(Human)
Duquesne University of The Holy Spirit
US Patent
Duquesne University of The Holy Spirit
US Patent
Affinity DataIC50: 83.1nMAssay Description:RTK inhibitory activity of the compounds 2-12 were evaluated using human tumor cells known to express high levels of EGFR, VEGFR-2 or PDFGR-β us...More data for this Ligand-Target Pair
TargetPlatelet-derived growth factor receptor alpha(Human)
Duquesne University of The Holy Spirit
US Patent
Duquesne University of The Holy Spirit
US Patent
Affinity DataIC50: 84nMAssay Description:RTK inhibitory activity of the compounds 2-12 were evaluated using human tumor cells known to express high levels of EGFR, VEGFR-2 or PDFGR-β us...More data for this Ligand-Target Pair
Affinity DataIC50: 90.3nMAssay Description:RTK inhibitory activity of the compounds 2-12 were evaluated using human tumor cells known to express high levels of EGFR, VEGFR-2 or PDFGR-β us...More data for this Ligand-Target Pair
Affinity DataIC50: 102nMAssay Description:RTK inhibitory activity of the compounds 2-12 were evaluated using human tumor cells known to express high levels of EGFR, VEGFR-2 or PDFGR-β us...More data for this Ligand-Target Pair
Affinity DataIC50: 103nMAssay Description:RTK inhibitory activity of the compounds 2-12 were evaluated using human tumor cells known to express high levels of EGFR, VEGFR-2 or PDFGR-β us...More data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 2(Human)
Duquesne University of The Holy Spirit
US Patent
Duquesne University of The Holy Spirit
US Patent
Affinity DataIC50: 121nMAssay Description:RTK inhibitory activity of the compounds 2-12 were evaluated using human tumor cells known to express high levels of EGFR, VEGFR-2 or PDFGR-β us...More data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 2(Human)
Duquesne University of The Holy Spirit
US Patent
Duquesne University of The Holy Spirit
US Patent
Affinity DataIC50: 125nMAssay Description:RTK inhibitory activity of the compounds 2-12 were evaluated using human tumor cells known to express high levels of EGFR, VEGFR-2 or PDFGR-β us...More data for this Ligand-Target Pair
TargetPlatelet-derived growth factor receptor alpha(Human)
Duquesne University of The Holy Spirit
US Patent
Duquesne University of The Holy Spirit
US Patent
Affinity DataIC50: 132nMAssay Description:RTK inhibitory activity of the compounds 2-12 were evaluated using human tumor cells known to express high levels of EGFR, VEGFR-2 or PDFGR-β us...More data for this Ligand-Target Pair
Affinity DataIC50: 162nMAssay Description:RTK inhibitory activity of the compounds 2-12 were evaluated using human tumor cells known to express high levels of EGFR, VEGFR-2 or PDFGR-β us...More data for this Ligand-Target Pair
TargetPlatelet-derived growth factor receptor alpha(Human)
Duquesne University of The Holy Spirit
US Patent
Duquesne University of The Holy Spirit
US Patent
Affinity DataIC50: 166nMAssay Description:RTK inhibitory activity of the compounds 2-12 were evaluated using human tumor cells known to express high levels of EGFR, VEGFR-2 or PDFGR-β us...More data for this Ligand-Target Pair
Affinity DataIC50: 172nMAssay Description:RTK inhibitory activity of the compounds 2-12 were evaluated using human tumor cells known to express high levels of EGFR, VEGFR-2 or PDFGR-β us...More data for this Ligand-Target Pair
TargetPlatelet-derived growth factor receptor alpha(Human)
Duquesne University of The Holy Spirit
US Patent
Duquesne University of The Holy Spirit
US Patent
Affinity DataIC50: 198nMAssay Description:RTK inhibitory activity of the compounds 2-12 were evaluated using human tumor cells known to express high levels of EGFR, VEGFR-2 or PDFGR-β us...More data for this Ligand-Target Pair
Affinity DataIC50: 226nMAssay Description:RTK inhibitory activity of the compounds 2-12 were evaluated using human tumor cells known to express high levels of EGFR, VEGFR-2 or PDFGR-β us...More data for this Ligand-Target Pair
Affinity DataIC50: 298nMAssay Description:RTK inhibitory activity of the compounds 2-12 were evaluated using human tumor cells known to express high levels of EGFR, VEGFR-2 or PDFGR-β us...More data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 2(Human)
Duquesne University of The Holy Spirit
US Patent
Duquesne University of The Holy Spirit
US Patent
Affinity DataIC50: >300nMAssay Description:RTK inhibitory activity of the compounds 2-12 were evaluated using human tumor cells known to express high levels of EGFR, VEGFR-2 or PDFGR-β us...More data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 2(Human)
Duquesne University of The Holy Spirit
US Patent
Duquesne University of The Holy Spirit
US Patent
Affinity DataIC50: >300nMAssay Description:RTK inhibitory activity of the compounds 2-12 were evaluated using human tumor cells known to express high levels of EGFR, VEGFR-2 or PDFGR-β us...More data for this Ligand-Target Pair
Affinity DataIC50: 307nMAssay Description:RTK inhibitory activity of the compounds 2-12 were evaluated using human tumor cells known to express high levels of EGFR, VEGFR-2 or PDFGR-β us...More data for this Ligand-Target Pair
Affinity DataIC50: >500nMAssay Description:RTK inhibitory activity of the compounds 2-12 were evaluated using human tumor cells known to express high levels of EGFR, VEGFR-2 or PDFGR-β us...More data for this Ligand-Target Pair
Affinity DataIC50: >500nMAssay Description:RTK inhibitory activity of the compounds 2-12 were evaluated using human tumor cells known to express high levels of EGFR, VEGFR-2 or PDFGR-β us...More data for this Ligand-Target Pair
Affinity DataIC50: >500nMAssay Description:RTK inhibitory activity of the compounds 2-12 were evaluated using human tumor cells known to express high levels of EGFR, VEGFR-2 or PDFGR-β us...More data for this Ligand-Target Pair
